rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CMND
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Clearmind completes patient recruitment for AUD trial segment
      Oct 27Investing.comCMND
      Clearmind submits FDA recommendations on psychedelic therapies
      Oct 7Investing.comCMND
      NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration With Clearmind Covering LSD, Ketamine and Ibogaine Combinations

      The U.S. Patent Applications Cover Proprietary Combinations of NeuroThera's PEA Technology With LSD, Ketamine and Ibogaine for Potential Therapeutic Applications, Including Mental Health Disorders, Such as Depression and PTSD as Well as Substance Use...

      Sep 23Yahoo FinanceCMND
      SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

      The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders TEL AVIV, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developi

      Sep 23Yahoo FinanceCMND
      Clearmind testifies at FDA hearing on psychedelic therapies
      Sep 17Investing.comCMND
      Clearmind enrolls first AUD patients in CMND-100 clinical trial
      Sep 11Investing.comCMND
      Clearmind Medicine Agrees to Acquire 51% Stake in Charging Robotics for $2.5 Million
      Sep 4Yahoo FinanceCMND
      Clearmind Medicine Stock Slides Friday: What's Happening?
      Sep 4BenzingaCMND
      Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis

      Charging Robotics is one of the few worldwide developing innovative wireless charging systems designed specifically for automated parking facilities and autonomous mobile platforms- environments where conventional cables and plug-in infrastructure cannot operate. Vancouver, Canada, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second

      Sep 4Yahoo FinanceCMND
      Clearmind Medicine to Acquire Majority Stake in Charging Robotics for $2.5 Million

      Clearmind Medicine (CMND) said Friday it will acquire a 51% stake in Charging Robotics, which develo

      Sep 4Yahoo FinanceCMND
      Clearmind to acquire 51% stake in EV charging firm for $2.5M
      Sep 4Investing.comCMND
      Clearmind initiates phase IIa trial for alcohol use disorder drug
      Sep 1Investing.comCMND
      NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

      U.S. Publication of a Patent Application Covering the MDMA-N-acylethanolamines Combination Expands Intellectual Property Generated Through the Collaboration, and Provides Guidance Addressing Clinical Development Considerations for Psychedelic Drugs, ...

      Aug 24Yahoo FinanceCMND
      SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
      Aug 24Yahoo FinanceCMNDSPRC

      This is the newest page. Registered accounts read further back.